ATE260111T1 - Mittel zur behandlung von autoimmunkrankheiten - Google Patents

Mittel zur behandlung von autoimmunkrankheiten

Info

Publication number
ATE260111T1
ATE260111T1 AT95913445T AT95913445T ATE260111T1 AT E260111 T1 ATE260111 T1 AT E260111T1 AT 95913445 T AT95913445 T AT 95913445T AT 95913445 T AT95913445 T AT 95913445T AT E260111 T1 ATE260111 T1 AT E260111T1
Authority
AT
Austria
Prior art keywords
autoimmune diseases
agents
treatment
glycoprotein
agent
Prior art date
Application number
AT95913445T
Other languages
English (en)
Inventor
Ivan Nikolaevich Golovistikov
Leonid Yazonovich Kacharava
Jury Semyonovich Tatarinov
Khallar Abdumuslimov Alikhanov
Original Assignee
Ivan Nikolaevich Golovistikov
Leonid Yazonovich Kacharava
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivan Nikolaevich Golovistikov, Leonid Yazonovich Kacharava filed Critical Ivan Nikolaevich Golovistikov
Application granted granted Critical
Publication of ATE260111T1 publication Critical patent/ATE260111T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT95913445T 1994-03-18 1995-03-16 Mittel zur behandlung von autoimmunkrankheiten ATE260111T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU9494008169A RU2056852C1 (ru) 1994-03-18 1994-03-18 Средство для лечения аутоиммунных заболеваний с иммунодефицитом супрессоров и способ лечения аутоиммунных заболеваний
PCT/RU1995/000047 WO1995025531A1 (en) 1994-03-18 1995-03-16 Means for treating auto-immune diseases and method of treatment

Publications (1)

Publication Number Publication Date
ATE260111T1 true ATE260111T1 (de) 2004-03-15

Family

ID=20153349

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95913445T ATE260111T1 (de) 1994-03-18 1995-03-16 Mittel zur behandlung von autoimmunkrankheiten

Country Status (22)

Country Link
US (1) US6150326A (de)
EP (1) EP0790059B1 (de)
JP (1) JPH09510473A (de)
KR (1) KR100382252B1 (de)
CN (1) CN1146156A (de)
AT (1) ATE260111T1 (de)
AU (1) AU699896B2 (de)
BG (1) BG62759B1 (de)
CA (1) CA2185892A1 (de)
CZ (1) CZ285856B6 (de)
DE (2) DE69532611D1 (de)
ES (1) ES2107980T1 (de)
FI (1) FI963671A7 (de)
GE (1) GEP20012377B (de)
GR (1) GR980300023T1 (de)
HU (1) HUT75720A (de)
NO (1) NO963911L (de)
PL (1) PL179765B1 (de)
RU (1) RU2056852C1 (de)
SK (1) SK281948B6 (de)
UA (1) UA26939C2 (de)
WO (1) WO1995025531A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2120298C1 (ru) * 1995-11-28 1998-10-20 Товарищество с ограниченной ответственностью "Верта" Иммуностимулятор и препарат на его основе
FR2747041B1 (fr) * 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
GB0030729D0 (en) * 2000-12-16 2001-01-31 Univ Nottingham Substituted-4-Quinolones
US20050032725A1 (en) * 2002-10-09 2005-02-10 Toerrx, Inc. Molecules preferentially associated with effector T cells or regulatory T cells and methods of their use
RU2303995C1 (ru) * 2006-04-28 2007-08-10 Халлар Абдумуслимович Алиханов Средство, обладающее иммунорегуляторным свойством и его применение для лечения аутоиммунных заболеваний

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0000938B1 (de) * 1977-08-22 1984-10-17 National Research Development Corporation Makromolekulare kovalente Konjugate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
JPS61186322A (ja) * 1985-02-13 1986-08-20 Nippon Univ 免疾調節剤
IT1188646B (it) * 1986-04-09 1988-01-20 Ellem Ind Farmaceutica Tripeptide ad attivita' immunostimolante
US4803072A (en) * 1986-09-10 1989-02-07 Smithkline Beckman Corporation Immunomodulation
FR2609632B1 (fr) * 1987-01-21 1991-03-29 Shelly Marc Nouvelle application therapeutique de la 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinon-6-one et les compositions pharmaceutiques destinees a cet usage
US5169835A (en) * 1989-01-18 1992-12-08 Oklahoma Medical Research Foundation Pregancy specific proteins applications
FR2650183A1 (fr) * 1989-07-25 1991-02-01 Pasteur Institut Proteines immunostimulantes, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et application de ces produits a des fins therapeutiques et de diagnostic
US5118669A (en) * 1989-09-20 1992-06-02 Hitachi Chemical Co., Ltd. Peptides and intermediates therefor useful as antiallergic agents, vasodilators and immunoregulators
US5559097A (en) * 1990-01-12 1996-09-24 Idaho Research Foundation, Inc. Use of a pregnancy specific protein as an immunosuppressive
RU1836957C (ru) * 1990-03-25 1993-08-30 2-й Московский государственный медицинский институт им.Н.И.Пирогова Способ получени трофобластического бета @ -гликопротеина
GB2251186A (en) * 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease

Also Published As

Publication number Publication date
HUT75720A (en) 1997-05-28
KR970701557A (ko) 1997-04-12
EP0790059A4 (de) 2000-11-02
BG62759B1 (bg) 2000-07-31
GR980300023T1 (en) 1998-04-30
NO963911D0 (no) 1996-09-18
NO963911L (no) 1996-11-08
DE790059T1 (de) 1998-03-12
WO1995025531A1 (en) 1995-09-28
AU699896B2 (en) 1998-12-17
PL316311A1 (en) 1997-01-06
SK118796A3 (en) 1997-06-04
US6150326A (en) 2000-11-21
FI963671L (fi) 1996-11-14
UA26939C2 (uk) 1999-12-29
BG100921A (bg) 1997-12-30
FI963671A7 (fi) 1996-11-14
EP0790059A1 (de) 1997-08-20
CZ274796A3 (en) 1997-06-11
FI963671A0 (fi) 1996-09-17
RU2056852C1 (ru) 1996-03-27
ES2107980T1 (es) 1997-12-16
KR100382252B1 (ko) 2003-07-07
PL179765B1 (pl) 2000-10-31
CA2185892A1 (en) 1995-09-28
HU9602558D0 (en) 1996-11-28
EP0790059B1 (de) 2004-02-25
SK281948B6 (sk) 2001-09-11
DE69532611D1 (de) 2004-04-01
GEP20012377B (en) 2001-03-25
JPH09510473A (ja) 1997-10-21
AU2087495A (en) 1995-10-09
CN1146156A (zh) 1997-03-26
CZ285856B6 (cs) 1999-11-17

Similar Documents

Publication Publication Date Title
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69333348D1 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv-verwandten krankheiten
EA199900494A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
DE69310677D1 (de) Behandlung von Brennstoffgasen, insbesondere für Brennstoffzellen und Vorrichtung dafür
DE3850026D1 (de) Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren.
BG95935A (bg) Метод и средство за приемане на дексмедетомидин директно през кожата
ATE466014T1 (de) Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
FI893916A0 (fi) Alfa-subenhet av lfa-1 -leukocytadhesionsreceptor.
EA200100103A1 (ru) Ингибиторы адгезии клеток
DE69822665D1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
ES2178668T4 (es) Naftilamidas como agentes del sistema nervioso central.
DE3782214D1 (de) Mittel zur behandlung des scheidenmilieus.
BR9808221A (pt) Método de tratamento de tumor.
DE3687097D1 (de) Therapeutisches mittel zur behandlung haematopoietischer krankheiten.
DE69504949D1 (de) Verwendung eines Antagonisten der Substanz P zur Behandlung von Hautrötungen neurogen Ursprungs
DE69532611D1 (de) Mittel zur behandlung von autoimmunkrankheiten
DE69838553D1 (de) Verfahren zur diagnose, prognose und behandlung von glaukom und verwandten erkrankungen
DE69007374D1 (de) Injektionssystem für die Behandlung von Zellen.
DE3777656D1 (de) Mittel zur behandlung von alopezien.
DE69508605D1 (de) Proinsulin-peptid-verbindungen für den nachweis und die behandlung von typ-i-diabetes
NL7804192A (nl) Cyclohexaancarbonzuur en de derivaten hiervan, evenals de toepassing van deze stoffen als therapeutisch mid- del.
PT77238A (de) Substituierte tert.-butanol-derivate verfahren zu ihrer herstellung und diese enthaltende antimykotische mittel
ES2149448T3 (es) Agentes terapeuticos y analiticos.
ES2169124T3 (es) Acido 4-aminomicofenolico 6-sustituido y derivados con actividad inmunosupresora.
DE3775278D1 (de) Topische methotrexatzubereitung zur behandlung hyperproliferativer epithelerkrankungen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties